严重肢体缺血患者一线治疗策略的一年结果(CRITISCH 注册研究)
CRITISCH 是一项在德国 27 个血管中心连续纳入 1200 例严重肢体缺血(CLI)患者的多中心前瞻性注册研究,评估所有一线治疗策略的结局。12 个月无截肢生存率在腔内治疗、旁路手术、股动脉补片成形和保守治疗中分别为 75%、72%、73% 和 72%,均达到血管外科学会建议的目标性能指标(71%)。慢性肾病是各血运重建方式后预后的重要决定因素。
要点
- 12个月无截肢生存率:腔内治疗75%、旁路手术72%、股动脉补片成形73%、保守治疗72%。
- 旁路术后无截肢生存率降低的独立危险因素:慢性肾病(HR 2.07)、人工血管旁路(HR 1.97)。
- 腔内治疗预后受损因素:慢性肾病(HR 1.47)和 Rutherford 6 级(HR 1.81)。
核心结论
- CRITISCH 注册数据显示,治疗医师选择并指示的所有一线治疗策略均达到建议的目标性能指标。
- 无论采用何种血运重建方式,慢性肾病均是治疗后患者预后的重要决定因素。
研究设计与样本
- CRITISCH(ClinicalTrials.gov 标识 NCT01877252)是一项多中心、全国性、前瞻性注册研究,评估德国 27 个血管中心连续 1200 例 CLI 患者中应用的所有可用治疗策略。
- 招募于 2013 年 1 月开始,2014 年 9 月完成。
- 治疗选项包括腔内血运重建(642 例,53.5%)、旁路手术(284 例,23.7%)、股动脉补片成形(126 例,10.5%)伴或不伴同期外周介入、保守治疗(118 例,9.8%)和一期大截肢(30 例,2.5%)。
- 主要终点为无截肢生存(AFS),采用血管外科学会建议的目标性能指标(OPG)71% 作为有效性标准。
- 采用多变量回归方法识别影响治疗选择和每种治疗后 AFS 的变量,结果以风险比(HR)和 95% 置信区间(CI)表示。
主要发现
- 腔内治疗、旁路移植、股动脉补片成形和保守治疗的 12 个月 AFS 估计值分别为 75%、72%、73% 和 72%。
- 影响治疗选择的因素包括年龄、慢性肾病(CKD)、糖尿病、吸烟、患肢既往血管手术、TransAtlantic Inter-Society Consensus II C/D 病变和无流出道血管。
- Cox 回归分析确定 CKD(HR 2.07,95% CI 1.26 至 3.41,p=0.004)、使用人工血管旁路移植物(HR 1.97,95% CI 1.23 至 3.14,p=0.004)和患肢既往血管介入(HR 1.52,95% CI 0.94 至 2.43,p=0.085)为旁路手术后 AFS 降低的独立危险因素。
- CKD(HR 1.47,95% CI 1.09 至 1.99,p=0.012)和 Rutherford 6 级(HR 1.81,95% CI 1.30 至 2.52,p<0.001)损害腔内血运重建的表现。
关键数值与推荐
- 血管外科学会建议的 AFS 目标性能指标(OPG)为 71%,用作有效性标准。
- 12 个月 AFS:腔内治疗 75%,旁路手术 72%,股动脉补片成形 73%,保守治疗 72%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To examine the outcomes of all first-line strategies for the treatment of critical limb ischemia (CLI), identify factors that influenced the treatment choice, and determine the risk of amputation or death after each treatment. METHODS: CRITISCH ( ClinicalTrials.gov identifier NCT01877252) is a multicenter, national, prospective registry evaluating all available treatment strategies applied in 1200 consecutive CLI patients in 27 vascular centers in Germany. The recruitment started in January 2013 and was completed in September 2014. Treatment options were endovascular revascularization (642, 53.5%), bypass surgery (284, 23.7%), femoral artery patchplasty (126, 10.5%) with or without concomitant peripheral intervention, conservative treatment (118, 9.8%), and primary major amputation (30, 2.5%). The primary endpoint of this study was amputation-free survival (AFS). The Society of Vascular Surgery's suggested objective performance goal (OPG) for AFS (71%) was used as the effectiveness criterion. Multivariable regression methods were employed to identify variables that influenced the treatment selection and AFS after each treatment; results are presented as the hazard ratio (HR) and 95% confidence interval (CI). RESULTS: The 12-month AFS estimates following endovascular therapy, bypass grafting, femoral patchplasty, and conservative treatment were 75%, 72%, 73%, and 72%, respectively. Factors influencing treatment choice were age, chronic kidney disease (CKD), diabetes, smoking, prior vascular procedures in the index leg, TransAtlantic Inter-Society Consensus II C/D lesions, and absence of runoff vessels. Cox regression analysis identified CKD (HR 2.07, 95% CI 1.26 to 3.41, p=0.004), the use of a prosthetic bypass conduit (HR 1.97, 95% CI 1.23 to 3.14, p=0.004), and previous vascular intervention in the index limb (HR 1.52, 95% CI 0.94 to 2.43, p=0.085) as independent risk factors for diminished AFS after bypass surgery. CKD (HR 1.47, 95% CI 1.09 to 1.99, p=0.012) and Rutherford category 6 (HR 1.81, 95% CI 1.30 to 2.52, p<0.001) compromised the performance of endovascular revascularization. CONCLUSION: CRITISCH registry data revealed that all first-line treatment strategies selected and indicated by the treating physicians met the suggested OPGs. CKD was an important determinant of patient prognosis after treatment regardless of the revascularization method.
引用
- Stavroulakis K, Borowski M, Torsello G, et al. One-Year Results of First-Line Treatment Strategies in Patients With Critical Limb Ischemia (CRITISCH Registry). J Endovasc Ther. 2018. PMID: 29968501. doi:10.1177/1526602818771383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。